• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

消融放疗重编程胰腺肿瘤微环境有利于免疫检查点阻断治疗。

Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy.

机构信息

Department of Biomedical Engineering and Environmental Sciences, National Tsing Hua University, Hsinchu 30013, Taiwan.

Radiation Biology Research Center, Institute for Radiologic Research, Chang Gung University/Chang Gung Memorial Hospital, Taoyuan 333323, Taiwan.

出版信息

Int J Mol Sci. 2021 Feb 19;22(4):2091. doi: 10.3390/ijms22042091.

DOI:10.3390/ijms22042091
PMID:33669885
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7923299/
Abstract

The low overall survival rate of patients with pancreatic cancer has driven research to seek a new therapeutic protocol. Radiotherapy (RT) is frequently an option in the neoadjuvant or palliative settings for pancreatic cancer treatment. This study explored the effect of RT protocols on the tumor microenvironment (TME) and their consequent impact on anti-programmed cell death ligand-1 (PD-L1) therapy. Using a murine orthotopic pancreatic tumor model, UN-KC-6141, RT-disturbed TME was examined by immunohistochemical staining. The results showed that ablative RT is more effective than fractionated RT at recruiting T cells. On the other hand, fractionated RT induces more myeloid-derived suppressor cell infiltration than ablative RT. The RT-disturbed TME presents a higher perfusion rate per vessel. The increase in vessel perfusion is associated with a higher amount of anti-PD-L1 antibody being delivered to the tumor. Animal survival is increased by anti-PD-L1 therapy after ablative RT, with 67% of treated animals surviving more than 30 days after tumor inoculation compared to a median survival time of 16.5 days for the control group. Splenocytes isolated from surviving animals were specifically cytotoxic for UN-KC-6141 cells. We conclude that the ablative RT-induced TME is more suited than conventional RT-induced TME to combination therapy with immune checkpoint blockade.

摘要

胰腺癌患者的总体生存率较低,这促使研究人员寻求新的治疗方案。放射治疗(RT)经常是胰腺癌新辅助或姑息治疗的选择。本研究探讨了 RT 方案对肿瘤微环境(TME)的影响及其对抗程序性细胞死亡配体-1(PD-L1)治疗的影响。使用 UN-KC-6141 鼠原位胰腺肿瘤模型,通过免疫组织化学染色检查 RT 扰乱的 TME。结果表明,消融性 RT 比分割性 RT 更有效地招募 T 细胞。另一方面,分割性 RT 比消融性 RT 诱导更多的髓系来源抑制细胞浸润。RT 扰乱的 TME 表现出更高的每血管灌注率。血管灌注的增加与更多的抗 PD-L1 抗体被输送到肿瘤有关。消融性 RT 后抗 PD-L1 治疗可提高动物存活率,与对照组中位存活时间为 16.5 天相比,接种肿瘤后超过 30 天存活的治疗动物比例为 67%。从存活动物中分离的脾细胞对 UN-KC-6141 细胞具有特异性细胞毒性。我们得出结论,与常规 RT 诱导的 TME 相比,消融性 RT 诱导的 TME 更适合与免疫检查点阻断联合治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0270/7923299/e0970ffaebcb/ijms-22-02091-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0270/7923299/2bb61f218b54/ijms-22-02091-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0270/7923299/9b08b910ad5e/ijms-22-02091-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0270/7923299/e22c7f1f344b/ijms-22-02091-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0270/7923299/80d90fb2aaf4/ijms-22-02091-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0270/7923299/6ab651e79506/ijms-22-02091-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0270/7923299/e0970ffaebcb/ijms-22-02091-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0270/7923299/2bb61f218b54/ijms-22-02091-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0270/7923299/9b08b910ad5e/ijms-22-02091-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0270/7923299/e22c7f1f344b/ijms-22-02091-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0270/7923299/80d90fb2aaf4/ijms-22-02091-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0270/7923299/6ab651e79506/ijms-22-02091-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0270/7923299/e0970ffaebcb/ijms-22-02091-g006.jpg

相似文献

1
Ablative Radiotherapy Reprograms the Tumor Microenvironment of a Pancreatic Tumor in Favoring the Immune Checkpoint Blockade Therapy.消融放疗重编程胰腺肿瘤微环境有利于免疫检查点阻断治疗。
Int J Mol Sci. 2021 Feb 19;22(4):2091. doi: 10.3390/ijms22042091.
2
PAK1 inhibition increases TRIM21-induced PD-L1 degradation and enhances responses to anti-PD-1 therapy in pancreatic cancer.PAK1 抑制增强了 TRIM21 诱导的 PD-L1 降解,并增强了对胰腺癌的抗 PD-1 治疗反应。
Biochim Biophys Acta Mol Basis Dis. 2024 Aug;1870(6):167236. doi: 10.1016/j.bbadis.2024.167236. Epub 2024 May 11.
3
Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.单细胞 RNA 测序揭示了抗 CD47 靶向治疗诱导的胰腺癌肿瘤浸润免疫细胞的区室重排。
J Hematol Oncol. 2019 Nov 27;12(1):124. doi: 10.1186/s13045-019-0822-6.
4
Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.PD-1 抑制剂和 OX40 激动剂的联合使用可在胰腺癌小鼠模型中诱导肿瘤排斥和免疫记忆。
Gastroenterology. 2020 Jul;159(1):306-319.e12. doi: 10.1053/j.gastro.2020.03.018. Epub 2020 Mar 14.
5
Reprogramming tumor immune microenvironment by milbemycin oxime results in pancreatic tumor growth suppression and enhanced anti-PD-1 efficacy.肟米先菌素重编程肿瘤免疫微环境导致胰腺肿瘤生长抑制和增强抗 PD-1 疗效。
Mol Ther. 2024 Sep 4;32(9):3145-3162. doi: 10.1016/j.ymthe.2024.07.029. Epub 2024 Aug 3.
6
In situ delivery of iPSC-derived dendritic cells with local radiotherapy generates systemic antitumor immunity and potentiates PD-L1 blockade in preclinical poorly immunogenic tumor models.局部放射治疗原位递送 iPSC 来源的树突状细胞可在临床前免疫原性低的肿瘤模型中产生全身抗肿瘤免疫并增强 PD-L1 阻断作用。
J Immunother Cancer. 2021 May;9(5). doi: 10.1136/jitc-2021-002432.
7
PI3Kγδ inhibitor plus radiation enhances the antitumour immune effect of PD-1 blockade in syngenic murine breast cancer and humanised patient-derived xenograft model.PI3Kγδ 抑制剂联合放疗增强 PD-1 阻断在同种小鼠乳腺癌和人源化患者来源异种移植模型中的抗肿瘤免疫效应。
Eur J Cancer. 2021 Nov;157:450-463. doi: 10.1016/j.ejca.2021.08.029. Epub 2021 Oct 1.
8
Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy.用抗 PD-L1 释放肿瘤免疫的刹车,并结合放射治疗用 L19-IL2 推动其加速器,可治愈免疫原性差的肿瘤。
J Immunother Cancer. 2021 Mar;9(3). doi: 10.1136/jitc-2020-001764.
9
PARP Inhibitor Upregulates PD-L1 Expression and Provides a New Combination Therapy in Pancreatic Cancer.聚腺苷二磷酸核糖聚合酶抑制剂上调程序性死亡配体 1 的表达,并为胰腺癌提供一种新的联合治疗策略。
Front Immunol. 2021 Dec 17;12:762989. doi: 10.3389/fimmu.2021.762989. eCollection 2021.
10
Combined α-programmed death-1 monoclonal antibody blockade and fractionated radiation therapy reduces tumor growth in mouse EL4 lymphoma.α-程序性死亡-1 单克隆抗体联合分割放疗可减少小鼠 EL4 淋巴瘤的肿瘤生长。
Cancer Biol Ther. 2019;20(5):666-679. doi: 10.1080/15384047.2018.1550569. Epub 2018 Dec 20.

引用本文的文献

1
Pancreatic cancer: failures and hopes-a review of new promising treatment approaches.胰腺癌:失败与希望——新的有前景的治疗方法综述
Explor Target Antitumor Ther. 2025 Mar 18;6:1002299. doi: 10.37349/etat.2025.1002299. eCollection 2025.
2
Power-Doppler-based NH002 microbubble sonoporation with chemotherapy relieves hypoxia and enhances the efficacy of chemotherapy and immunotherapy for pancreatic tumors.基于功率多普勒的 NH002 微泡超声破坏联合化疗缓解胰腺肿瘤缺氧并增强化疗和免疫治疗效果。
Sci Rep. 2024 Jun 3;14(1):8532. doi: 10.1038/s41598-024-54432-y.
3
Overcoming the limitations of immunotherapy in pancreatic ductal adenocarcinoma: Combining radiotherapy and metabolic targeting therapy.

本文引用的文献

1
Multimodal Mapping of the Tumor and Peripheral Blood Immune Landscape in Human Pancreatic Cancer.人类胰腺癌的肿瘤和外周血免疫景观的多模态图谱。
Nat Cancer. 2020 Nov;1(11):1097-1112. doi: 10.1038/s43018-020-00121-4. Epub 2020 Oct 26.
2
Therapy-Induced Modulation of the Tumor Microenvironment: New Opportunities for Cancer Therapies.治疗诱导的肿瘤微环境调节:癌症治疗的新机遇
Front Oncol. 2020 Oct 23;10:582884. doi: 10.3389/fonc.2020.582884. eCollection 2020.
3
Role of Myeloid-Derived Suppressor Cells in High-Dose-Irradiated TRAMP-C1 Tumors: A Therapeutic Target and an Index for Assessing Tumor Microenvironment.
克服胰腺导管腺癌免疫治疗的局限性:联合放疗与代谢靶向治疗。
J Cancer. 2024 Feb 12;15(7):2003-2023. doi: 10.7150/jca.92502. eCollection 2024.
4
Radiation Therapy and Myeloid-Derived Suppressor Cells: Breaking Down Their Cancerous Partnership.放射治疗与髓系来源抑制细胞:打破癌症相关伙伴关系。
Int J Radiat Oncol Biol Phys. 2024 May 1;119(1):42-55. doi: 10.1016/j.ijrobp.2023.11.050. Epub 2023 Nov 30.
5
Complete Remission of Widely Metastatic Human Epidermal Growth Factor Receptor 2-Amplified Pancreatic Adenocarcinoma After Precision Immune and Targeted Therapy With Description of Sequencing and Organoid Correlates.精准免疫和靶向治疗后广泛转移的人表皮生长因子受体2扩增胰腺癌完全缓解,并描述测序及类器官相关性
JCO Precis Oncol. 2023 Apr;7:e2100489. doi: 10.1200/PO.21.00489.
6
The current understanding of the immune landscape relative to radiotherapy across tumor types.当前对各种肿瘤类型的放射治疗相关免疫景观的理解。
Front Immunol. 2023 Mar 16;14:1148692. doi: 10.3389/fimmu.2023.1148692. eCollection 2023.
7
Role of tumor microenvironment in cancer progression and therapeutic strategy.肿瘤微环境在癌症进展和治疗策略中的作用。
Cancer Med. 2023 May;12(10):11149-11165. doi: 10.1002/cam4.5698. Epub 2023 Feb 21.
8
Radiotherapy as a means to increase the efficacy of T-cell therapy in solid tumors.放疗作为提高实体瘤中 T 细胞疗法疗效的手段。
Oncoimmunology. 2022 Dec 22;12(1):2158013. doi: 10.1080/2162402X.2022.2158013. eCollection 2023.
9
Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites.抗 4-1BB 免疫疗法增强了放疗的全身免疫效应,诱导 B 和 T 细胞依赖的抗肿瘤免疫激活,并改善了未照射部位的肿瘤控制。
Cancer Immunol Immunother. 2023 Jun;72(6):1445-1460. doi: 10.1007/s00262-022-03325-y. Epub 2022 Dec 5.
10
Study protocol for a prospective, open-label, single-arm, phase II study on the combination of tislelizumab, nab-paclitaxel, gemcitabine, and concurrent radiotherapy as the induction therapy for patients with locally advanced and borderline resectable pancreatic cancer.一项关于替雷利珠单抗、白蛋白结合型紫杉醇、吉西他滨联合同步放疗作为局部晚期和可切除边缘胰腺癌患者诱导治疗的前瞻性、开放标签、单臂、II期研究的研究方案。
Front Oncol. 2022 Aug 18;12:879661. doi: 10.3389/fonc.2022.879661. eCollection 2022.
髓系来源抑制细胞在大剂量照射的 TRAMP-C1 肿瘤中的作用:一个治疗靶点和评估肿瘤微环境的指标。
Int J Radiat Oncol Biol Phys. 2021 Apr 1;109(5):1547-1558. doi: 10.1016/j.ijrobp.2020.11.004. Epub 2020 Nov 12.
4
Radiation Therapy and the In Situ Vaccination Approach.放射治疗与原位疫苗接种方法。
Int J Radiat Oncol Biol Phys. 2020 Nov 15;108(4):891-898. doi: 10.1016/j.ijrobp.2020.08.023. Epub 2020 Aug 12.
5
Cancer statistics, 2020.癌症统计数据,2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
6
Assessing the Magnitude of Immunogenic Cell Death Following Chemotherapy and Irradiation Reveals a New Strategy to Treat Pancreatic Cancer.评估化疗和放疗后免疫细胞死亡的程度揭示了治疗胰腺癌的新策略。
Cancer Immunol Res. 2020 Jan;8(1):94-107. doi: 10.1158/2326-6066.CIR-19-0373. Epub 2019 Nov 12.
7
Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment.立体定向体部放疗和白细胞介素-12 联合治疗通过重极化免疫微环境根除胰腺肿瘤。
Cell Rep. 2019 Oct 8;29(2):406-421.e5. doi: 10.1016/j.celrep.2019.08.095.
8
A translational concept of immuno-radiobiology.免疫放射生物学的转化概念。
Radiother Oncol. 2019 Nov;140:116-124. doi: 10.1016/j.radonc.2019.06.001. Epub 2019 Jul 1.
9
Radiotherapy Both Promotes and Inhibits Myeloid-Derived Suppressor Cell Function: Novel Strategies for Preventing the Tumor-Protective Effects of Radiotherapy.放射治疗既能促进也能抑制髓源性抑制细胞功能:预防放射治疗肿瘤保护作用的新策略。
Front Oncol. 2019 Apr 2;9:215. doi: 10.3389/fonc.2019.00215. eCollection 2019.
10
Immunotherapy and Prevention of Pancreatic Cancer.胰腺癌的免疫治疗与预防
Trends Cancer. 2018 Jun;4(6):418-428. doi: 10.1016/j.trecan.2018.04.001. Epub 2018 Apr 30.